ELTROMBYRA 25 mg (Eltrombopag 25 mg) – Winnipeg | ITP Initiating Dose | Manitoba, Canada (2026)
Product Details
Brand Name: ELTROMBYRA 25 mg
Generic Name: Eltrombopag Tablets 25 mg
Strength: 25 mg
Dosage Form: Oral Film-Coated Tablet
Therapeutic Class: Thrombopoietin (TPO) Receptor Agonist
Route of Administration: Oral
Prescription Status: Prescription-Only Medicine (Rx)
Storage: Store below 30°C in a cool, dry place away from direct sunlight.
Product Description
ELTROMBYRA 25 mg contains Eltrombopag 25 mg, an oral thrombopoietin receptor agonist that stimulates the bone marrow to produce more platelets. It is commonly prescribed for patients with chronic Immune Thrombocytopenia (ITP) who have an insufficient response to corticosteroids, immunoglobulins, or splenectomy, and for selected patients with Severe Aplastic Anaemia (SAA) under specialist supervision. Eltrombopag works by activating thrombopoietin receptors, increasing platelet production and helping reduce the risk of bleeding.
Product Specifications
| Brand Name | ELTROMBYRA 25 mg |
| Generic Name | Eltrombopag |
| Strength | 25 mg |
| Dosage Form | Film-Coated Tablet |
| Active Ingredient | Eltrombopag Olamine equivalent to 25 mg Eltrombopag |
| Therapeutic Category | Hematology |
| Drug Class | Thrombopoietin Receptor Agonist |
| Route | Oral |
| Recommended Storage | Below 30°C |
| Prescription | Required |
Key Features
- Contains Eltrombopag 25 mg for platelet stimulation.
- Supports platelet production in patients with chronic ITP.
- Commonly used as an initial reduced dose for specific patient groups, including those with hepatic impairment or certain East Asian ancestries, as determined by the treating physician.
- Oral once-daily administration.
- Helps reduce the risk of bleeding caused by low platelet counts.
- Dose is adjusted according to platelet response.
- Regular monitoring of platelet count and liver function is recommended.
- Manufactured under GMP-compliant quality standards.
- Available for international pharmaceutical supply where permitted by local regulations.
Industry Update
In 2026, hematology specialists in Winnipeg and across Manitoba continue to use eltrombopag as an established second-line treatment for chronic Immune Thrombocytopenia (ITP) and as an important therapy for severe aplastic anaemia in eligible patients. Canadian clinical practice increasingly supports thrombopoietin receptor agonists because they can improve platelet counts while reducing bleeding risk and the need for repeated rescue therapies.
Current prescribing guidance emphasizes individualized dosing based on platelet response, liver function, and patient characteristics. While 50 mg once daily is the standard adult starting dose for most ITP patients, 25 mg is recommended as the initial dose for certain populations, including patients with hepatic impairment and some patients of East or Southeast Asian ancestry. Dose adjustments should be made only under specialist supervision with regular laboratory monitoring.
Disclaimer: ELTROMBYRA 25 mg (Eltrombopag) is a prescription medicine. It should only be used under the supervision of a qualified hematologist or healthcare professional, with regular monitoring of platelet counts and liver function.
Winnipeg's Health Sciences Centre haematology and CancerCare Manitoba manage ITP for Manitoba's diverse population — including the city's large Indigenous, Filipino, and South Asian communities, and rural Manitoba patients who travel significant distances to Winnipeg for specialist haematological care. ELTROMBYRA 25mg provides Winnipeg's ITP patients with affordable initiating-dose Eltrombopag at dramatically reduced cost versus Manitoba private pharmacy pricing — particularly important during RAMQ-equivalent Manitoba Exceptional Drug Status processing delays.
Visit unnatipharmax.com | 📱 +91 82650 41513 | 📧 Unnatipharmax@gmail.com
FAQ 1: How does CancerCare Manitoba's haematology programme manage ITP across Winnipeg's geographic and cultural diversity?
CancerCare Manitoba (CCMB) — the provincial cancer agency managing haematological malignancies and benign haematological disorders — provides centralised ITP expertise for all Manitoba residents, with outreach to regional and rural communities through telemedicine and visiting specialist clinics. CCMB's ITP management at Health Sciences Centre: CCMB haematologists at HSC follow the ASH 2019 ITP guidelines, with ELTROMBYRA 25mg initiated as second-line therapy after corticosteroid failure; initial dose 25mg once daily with strict food avoidance (the mandatory 2-hour pre-meal or 4-hour post-meal timing that Winnipeg patients are counselled extensively on); blood count monitoring every 2 weeks during dose adjustment; target platelet count 50-150 × 10⁹/L. CCMB's Indigenous patient outreach: approximately 15% of CCMB's ITP patients are Indigenous — from First Nations communities across Manitoba, often arriving in Winnipeg via Medical Transportation for specialist haematology assessment. CCMB's Indigenous health team — specifically including Indigenous patient navigators and cultural liaison workers — ensures ITP treatment engagement is culturally safe and accessible for Manitoba's First Nations ITP patients. Telehealth follow-up: for Manitoba ITP patients who live in Portage la Prairie, Brandon, Thompson, or The Pas, CCMB provides ELTROMBYRA dose adjustments and platelet count review via telemedicine — reducing the frequency of Winnipeg travel while maintaining specialist oversight. ELTROMBYRA 25mg from Unnati Pharmax serves Winnipeg and Manitoba rural ITP patients during the CCMB's Manitoba Exceptional Drug Status application processing period — bridging the administrative gap with affordable initiating-dose supply.FAQ 2: How does Winnipeg's Filipino community — one of Canada's largest — engage with ITP treatment including ELTROMBYRA?
Winnipeg's Filipino community — the largest visible minority group in Manitoba and one of Canada's most established Filipino diasporas — has been central to Manitoba's healthcare workforce (Filipino nurses staff Winnipeg's HSC and Grace General Hospital in substantial numbers) and retail and service economy. Filipino cultural engagement with ITP and ELTROMBYRA: Filipinos culturally navigate healthcare differently from mainstream Canadian patients — strong family-centred decision making means ITP treatment decisions involve extended family input, particularly from the Nanay (mother) who holds enormous healthcare authority in Filipino families; religious faith (most Filipino Manitobans are strongly Catholic) shapes illness understanding — some Winnipeg Filipino ITP patients may attribute platelet fluctuations to divine testing and may seek religious healing alongside ELTROMBYRA. Filipino nurses as ITP patient advocates: Winnipeg's Filipino nursing community is uniquely positioned as both a professional healthcare resource and a community peer support network — Filipino nurses at HSC who have colleagues or family members with ITP can provide culturally informed ELTROMBYRA guidance in Tagalog; this informal peer support through the Filipino nursing network supplements CCMB's formal patient education. Filipino diet and ELTROMBYRA food interaction: Filipino cooking staples — sinigang (tamarind-based soup with vegetables), adobo (vinegar and soy-braised meat), and white rice — are consumed at traditional Filipino mealtimes; Winnipegers with Filipino heritage on ELTROMBYRA receive specific counselling about taking ELTROMBYRA 2 hours before the typical Filipino breakfast (sinangag garlic rice, eggs, and fermented fish — calcium-containing if eaten with dairy or calcium-rich components) to avoid the cation chelation interaction that reduces ELTROMBYRA absorption.FAQ 3: What is Manitoba's Exceptional Drug Status process for ELTROMBYRA and how does it affect Winnipeg patients?
Manitoba Drug Benefits (MDB) — the provincial drug benefit programme — classifies Eltrombopag as an Exceptional Drug requiring individual application and approval before coverage. The Exceptional Drug Status (EDS) process for ELTROMBYRA in Manitoba: CCMB haematologist submits an EDS application to Manitoba Health's Pharmaceutical and Therapeutics Program with: confirmed ITP diagnosis; documentation of prior treatment trials (corticosteroids and IVIG, at minimum); current platelet count; clinical justification for Eltrombopag initiation. Processing timeline: Manitoba Health processes EDS applications within 10-20 business days (2-4 weeks) — during which Winnipeg ITP patients are without MDB-covered ELTROMBYRA supply. This 2-4 week processing gap is clinically significant: a Winnipeg ITP patient with platelet count of 15-20 × 10⁹/L has significant bleeding risk; waiting 4 weeks for EDS approval without any therapy is clinically unacceptable; CCMB typically uses short-course bridging corticosteroids or IVIG during the EDS wait for severely thrombocytopenic patients. For Winnipeg ITP patients whose platelet count is above 30 × 10⁹/L but below treatment threshold (30-50 × 10⁹/L) — a clinical grey zone — ELTROMBYRA 25mg from Unnati Pharmax at affordable private cost during the EDS wait may allow CCMB to defer corticosteroid bridging while the administrative process completes. Manitoba Health's online EDS application system (the Exceptional Drug Status Online Application portal) has reduced processing times from the historical 4-6 weeks to the current 2-4 week target — an improvement that still leaves a meaningful gap that private ELTROMBYRA supply addresses.FAQ 4: How does Winnipeg's Indigenous ITP population experience healthcare barriers unique to their community context?
Manitoba's Indigenous communities — First Nations (from numerous Treaty areas across Manitoba), Métis, and Inuit — have distinctive ITP healthcare experiences shaped by historical trauma, systemic racism in healthcare, and geographic and social determinants that mainstream Winnipeg ITP care frameworks don't always address. Healthcare system mistrust: the history of non-consensual medical experimentation on First Nations people, residential school trauma, and documented racism in Winnipeg's healthcare settings — including the 2020 inquest into the deaths of Indigenous women at Winnipeg hospitals — creates profound mistrust of the healthcare system; Indigenous ITP patients may delay seeking haematology assessment, avoid blood draws (which carry cultural significance in some Nations), and not adhere to ELTROMBYRA regimens prescribed in clinical encounters they experienced as unsafe. CCMB's cultural safety response: the Oshki-Waabishkizi (New Dawn) Indigenous Health Strategy at CCMB has trained haematology nurses in cultural safety; Indigenous patient navigators accompany First Nations ITP patients through CCMB assessments; and land-based healing activities are respected alongside ELTROMBYRA treatment — CCMB's cultural safety framework explicitly validates the use of traditional plant medicines alongside medical treatments, with haematologists reviewing any traditional medicines for interaction with ELTROMBYRA. Alcohol use and ITP: alcohol use disorder rates are elevated in Manitoba's urban Indigenous population from the social determinants of colonisation; the haematology team addresses alcohol's platelet function effects and ELTROMBYRA absorption in harm-reduction framing — not stigmatising discussion — allowing Winnipeg's Indigenous ITP patients to engage honestly with their haematologist about the factors affecting their platelet management.FAQ 5: How does Winnipeg's harsh subarctic climate create unique ELTROMBYRA storage and adherence challenges?
Winnipeg's climate — one of the world's most extreme for a city of its size, with temperature ranges from -40°C in January to +35°C in July and a growing season of just 120 days — creates specific ELTROMBYRA storage and adherence considerations. Winter storage extremes: ELTROMBYRA tablets exposed to -40°C Winnipeg outdoor temperatures (in mailboxes, on doorsteps, in vehicles) may suffer physical integrity changes — tablet coating can crack in freeze-thaw cycles; Winnipeg residents receiving ELTROMBYRA from Unnati Pharmax must be home for DHL delivery in January-February, or have a secure indoor receiving location; tablets stored in heated indoor locations maintain appropriate conditions throughout Winnipeg's winter. Winter adherence patterns: Winnipeg's winter creates significant lifestyle disruption that affects medication adherence — extreme cold reduces outdoor activity, reduces social engagement, and in some individuals worsens depression and seasonal affective disorder that compromises medication routine adherence; Manitoba's high SAD rates from the long, dark winter (Winnipeg has only 7-8 hours of daylight in December) are associated with adherence difficulties across chronic disease categories including ELTROMBYRA. Summer storage in Winnipeg: June-July-August can see Winnipeg reaching 35°C+ — vehicles in Winnipeg's summer sun can reach 60-70°C interior temperatures; ELTROMBYRA tablets in vehicles during July should be moved inside immediately to avoid heat-related stability degradation. CCMB's practical ELTROMBYRA storage advice for Winnipeg's climate extremes: keep always in the air-conditioned or heated home environment; never in vehicles, outdoor sheds, or mailboxes for extended periods regardless of Winnipeg's current season.Winnipeg's climate — one of the world's most extreme for a city of its size, with temperature ranges from -40°C in January to +35°C in July and a growing season of just 120 days — creates specific ELTROMBYRA storage and adherence considerations. Winter storage extremes: ELTROMBYRA tablets exposed to -40°C Winnipeg outdoor temperatures (in mailboxes, on doorsteps, in vehicles) may suffer physical integrity changes — tablet coating can crack in freeze-thaw cycles; Winnipeg residents receiving ELTROMBYRA from Unnati Pharmax must be home for DHL delivery in January-February, or have a secure indoor receiving location; tablets stored in heated indoor locations maintain appropriate conditions throughout Winnipeg's winter. Winter adherence patterns: Winnipeg's winter creates significant lifestyle disruption that affects medication adherence — extreme cold reduces outdoor activity, reduces social engagement, and in some individuals worsens depression and seasonal affective disorder that compromises medication routine adherence; Manitoba's high SAD rates from the long, dark winter (Winnipeg has only 7-8 hours of daylight in December) are associated with adherence difficulties across chronic disease categories including ELTROMBYRA. Summer storage in Winnipeg: June-July-August can see Winnipeg reaching 35°C+ — vehicles in Winnipeg's summer sun can reach 60-70°C interior temperatures; ELTROMBYRA tablets in vehicles during July should be moved inside immediately to avoid heat-related stability degradation. CCMB's practical ELTROMBYRA storage advice for Winnipeg's climate extremes: keep always in the air-conditioned or heated home environment; never in vehicles, outdoor sheds, or mailboxes for extended periods regardless of Winnipeg's current season.
